anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Cannabidiol
Trial phase: Phase 3
ATC code: N03AX24
SMILES: C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 9
Group description: Following completion of the Pilot Phase (NCT02953548), participants were eligible to participate in the Open Label Extension Phase. Participants continued on the same dose administered in the Pilot Phase for a maximum of 1 year and completed a 10-day taper after completing the study or withdrawing. Participants were administered GWP42003-P oral solution (OS) orally, twice daily, or three times daily if poorly tolerated. The dosage was split evenly across the two or three daily administrations to equal the target or most tolerable dose.
Eligibility criteria:
Only participants who completed the pilot or pivotal phases of the trial may proceed to take part in this open-label extension phase of the trial.

Key eligibility criteria for the blinded phase were as follows:

Key Inclusion Criteria:

Participant is diagnosed with IS and has failed to respond adequately following treatment with 1 or more approved IS therapies.

Key Exclusion Criteria:

Participant is currently taking or has taken clobazam or any mammalian target of rapamycin (mTOR) inhibitor within the 2 weeks prior to the screening visit.
Participant has a QT interval, corrected for heart rate with Bazett's formula (QTcB), of 460 msec or greater on ECG.
Participant's caregiver is currently giving or has given recreational or medicinal cannabis, or synthetic cannabinoid-based medications, within the 1 month prior to the screening visit.
Participant's caregiver is unwilling to abstain from giving the participant (including the participant's mother abstaining themselves, if breastfeeding)recreational or medicinal cannabis, or synthetic cannabinoid-based medications (other than the study drug) during the trial.
Participant has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the study drug, such as sesame oil.
Participant has significantly impaired hepatic function at the screening visit.
Participant has received an investigational medicinal product as part of a clinical trial within a minimum of 5 half-lives prior to the screening visit.
Intervention: Bexagliflozin
Trial phase: Phase 1
ATC code: A10BK08
SMILES: OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 18
Group description: Bexagliflozin: Bexagliflozin tablets, 20 mg
Eligibility criteria:
Inclusion Criteria:

Subjects with body-mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2
Subjects who are non-smokers for at least 3 months prior to screening
Subjects who are willing and able to be confined to the clinical research facility as required by the protocol

Exclusion Criteria:

Subjects with a clinically significant history of allergy to drugs or latex.
Subjects with a history of alcohol or drug dependence in the past 12 months.
Subjects who have donated a significant amount of blood in the past 2 months
Female subjects who are pregnant or breastfeeding
Subjects who are not willing to use an adequate form of birth control during the study and for 30 days after discharge from clinic
Subjects who have taken an investigational drug in the past 30 days or 7 half-lives of the investigational drug, whichever is longer
Subjects who had previously received anti-diabetic medication, including metformin, sitagliptin, glimepiride or drugs of the same class (i.e. biguanides, DPP-4 inhibitors or sulfonylureas), or SGLT2 inhibitors, in the past 3 months
Intervention: Glimepiride
Trial phase: Phase 1
ATC code: A10BB12 | A10BD04 | A10BD06
SMILES: CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 18
Group description: Glimepiride: Glimepiride tablets, 2 mg
Eligibility criteria:
Inclusion Criteria:

Subjects with body-mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2
Subjects who are non-smokers for at least 3 months prior to screening
Subjects who are willing and able to be confined to the clinical research facility as required by the protocol

Exclusion Criteria:

Subjects with a clinically significant history of allergy to drugs or latex.
Subjects with a history of alcohol or drug dependence in the past 12 months.
Subjects who have donated a significant amount of blood in the past 2 months
Female subjects who are pregnant or breastfeeding
Subjects who are not willing to use an adequate form of birth control during the study and for 30 days after discharge from clinic
Subjects who have taken an investigational drug in the past 30 days or 7 half-lives of the investigational drug, whichever is longer
Subjects who had previously received anti-diabetic medication, including metformin, sitagliptin, glimepiride or drugs of the same class (i.e. biguanides, DPP-4 inhibitors or sulfonylureas), or SGLT2 inhibitors, in the past 3 months
Intervention: Betamethasone
Trial phase: Not Applicable
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 70
Group description: 35 patients in this group underwent the whitening procedure using the Dexamethasone acetate intervention.

Dexamethasone acetate: The volunteers in this group received 6 capsules of dexamethasone 8 mg each to be administered orally, initially two days before the first bleaching query as follows: 8 mg (1 capsule) 9 am two days before the first clinical session whitening; 8 mg 9 am to 1 day before session whitening, 8 mg 9 am on the day of the first session of whitening.Clinical intervention: 1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A placebo was applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
Eligibility criteria:
Inclusion Criteria:

The selected volunteers should present a good general state of health, be at least 18 years of age, regardless of gender, color / race and ethnicity, sexual orientation, and gender identity.
Volunteers must have an acceptable oral hygiene, present the upper and lower arches without absence of teeth of first premolar right to the left first premolar.
These elements have to be healthy, that is, not having any kind of restoration.
Volunteers must sign the consent form and clarification, have committed to return for periodic examinations and belong to the group of nonsmokers.

Exclusion Criteria:

Do not have medical history of diseases that can affect the results of the study;
subjects could not have made use of cigarettes in the last 30 days; have some important pathology in the oral cavity;
not being pregnant and also are not breastfeeding;
having any history of sensitivity or adverse reactions to anti-inflammatory used in the study;
not having calculations or advanced periodontal disease;
have not consumed drugs, alcohol or any medication that can cover the results, as other types of anti-inflammatories or painkillers;
The volunteers should not have used products indicated for dental sensitivity, as desensitizing toothpaste or similar product and not present recession or exacerbated hypersensitivity history.
Intervention: POTASSIUM NITRATE
Trial phase: Not Applicable
SMILES: O=[N+]([O-])[O-].[K+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 70
Group description: 35 patients in this group underwent the whitening procedure using the Potassium Nitrate intervention

Potassium Nitrate: The volunteers in the Potassium Nitrate Group (Placebo group) received 6 placebo capsules, who contained the same components of de dexamethasone drug except the active ingredient (starch [50%], lactose monohydrate [35%], dibasic calcium phosphate [14%], and magnesium stearate [1%]).Clinical session:1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A desensitizing gel containing 6% potassium nitrate will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
Eligibility criteria:
Inclusion Criteria:

The selected volunteers should present a good general state of health, be at least 18 years of age, regardless of gender, color / race and ethnicity, sexual orientation, and gender identity.
Volunteers must have an acceptable oral hygiene, present the upper and lower arches without absence of teeth of first premolar right to the left first premolar.
These elements have to be healthy, that is, not having any kind of restoration.
Volunteers must sign the consent form and clarification, have committed to return for periodic examinations and belong to the group of nonsmokers.

Exclusion Criteria:

Do not have medical history of diseases that can affect the results of the study;
subjects could not have made use of cigarettes in the last 30 days; have some important pathology in the oral cavity;
not being pregnant and also are not breastfeeding;
having any history of sensitivity or adverse reactions to anti-inflammatory used in the study;
not having calculations or advanced periodontal disease;
have not consumed drugs, alcohol or any medication that can cover the results, as other types of anti-inflammatories or painkillers;
The volunteers should not have used products indicated for dental sensitivity, as desensitizing toothpaste or similar product and not present recession or exacerbated hypersensitivity history.
Intervention: Ketorolac
Trial phase: Phase 2
ATC code: M01AB15 | S01BC05 | S01FB51
SMILES: O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 118
Group description: Postoperative recovery will follow the usual service protocols at our institution. Participants in this group may receive intravenous ketorolac (toradol) for pain control
Eligibility criteria:
Inclusion Criteria:

1. Women undergoing a non-urgent or elective cesarean delivery >37 weeks gestation

Exclusion Criteria:

Women undergoing an urgent or emergent cesarean birth
Women less than 18 years old
Patients receiving general anesthesia
Abnormally adherent placenta (Placenta Accreta) or expected excessive blood loss (Placenta accreta)
Pre-existing essential hypertension or hypertensive disorders of pregnancy (preeclampsia, eclampsia, HELLP)
Chronic or acute renal impairment
Bleeding disorders or platelet dysfunction
Peptic ulcer disease or gastrointestinal bleeding
Known hypersensitivity to ketorolac (toradol)
Active infection at the time of cesarean
Cesarean birth prior to 37 weeks
Women in significant pain in labor
Intervention: Propranolol
Trial phase: Phase 4
ATC code: C07AA05 | C07BA05 | C07FX01
SMILES: CC(C)NCC(O)COc1cccc2ccccc12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 13
Group description: One half of qualifying and consenting subjects will be randomized to receive propranolol. This group will receive study drug 3 times daily (every 8 hours) starting at 20 mg. The dosage may be increased by up to 60 mg/day divided over three daily doses (or an additional 20 mg/dose) as necessary until the heart rate is less than 100. Study drug will be held for hypotension (systolic <100) or bradycardia (heart rate <60 beats per minute). The maximum daily dose for the treatment of hypertension of 640 mg will not be exceeded in this study.

Propranolol
Eligibility criteria:
Inclusion Criteria:

Subjects ages 18 and older with isolated traumatic brain injury as defined by Glasgow Coma Scale score 12 or less with documented injury on head CT and limited injury to the rest of the body. (Abbreviated Injury Scale (AIS) must be < or = 3 from other body areas.)

Exclusion Criteria:

Subjects <18 years of age, prisoners, those on beta-blockers as home medication, those who are pregnant, those with severe liver disease, those taking vasopressors, those with acute coronary syndrome, and those with severe injury to another body region (AIS >3).
Subjects who cannot be enrolled within 48 hours of admission following acute resuscitation will not be enrolled into this study.
Intervention: Dapsone
Trial phase: Phase 4
ATC code: D10AX05 | J04BA02 | J04BA50 | J04BA51
SMILES: Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 17
Group description: Participants applied ACZONE 7.5 % gel topically, once-daily to the entire face, neck, upper chest, upper back and shoulders starting from Day 1 under maximal use conditions (2 grams per day) for Day 8 consecutive days, followed by a thin layer to their face and acne-affected areas on the upper chest, upper back, and shoulders for next 11 weeks.
Eligibility criteria:
Inclusion Criteria:

-Has acne vulgaris on the face, including the nose, with 20 to 100 total lesions (noninflammatory and/or inflammatory).

Exclusion Criteria:

Has uncontrolled systemic disease(s)
Has severe cystic acne, acne conglobata, acne fulminans, or secondary acne (chloracne, drug-induced acne)
Has used topical dapsone within 1 month prior to the screening
Has used oral dapsone within 2 months prior to screening.
Intervention: Dapsone
Trial phase: Phase 4
ATC code: D10AX05 | J04BA02 | J04BA50 | J04BA51
SMILES: Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 83
Group description: Participants applied ACZONE 7.5% gel topically, once-daily in a thin layer to their face and acne-affected areas on upper chest, upper back, and shoulders for 12 weeks.
Eligibility criteria:
Inclusion Criteria:

-Has acne vulgaris on the face, including the nose, with 20 to 100 total lesions (noninflammatory and/or inflammatory).

Exclusion Criteria:

Has uncontrolled systemic disease(s)
Has severe cystic acne, acne conglobata, acne fulminans, or secondary acne (chloracne, drug-induced acne)
Has used topical dapsone within 1 month prior to the screening
Has used oral dapsone within 2 months prior to screening.
Intervention: Bupivacaine
Trial phase: Phase 2 | Phase 3
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 80
Group description: Liposomal bupivacaine will be infiltrated

Liposomal bupivacaine: liposomal bupivacaine injection in the Pfannenstiel incision
Eligibility criteria:
Inclusion Criteria:

Scheduled cesarean delivery via Pfannenstiel incision;
Planned neuraxial anesthetic with intrathecal morphine and fentanyl administration.

Exclusion Criteria:

Current or prior use of methadone, buprenorphine, or other opioids before cesarean delivery;
Contraindication to neuraxial anesthetic;
Allergy to local anesthetic;
Planned general anesthetic.
Intervention: Scopolamine
Trial phase: Phase 4
ATC code: A04AD01 | A04AD51 | N05CM05 | S01FA02
SMILES: CN1C2CC(OC(=O)C(CO)c3ccccc3)CC1C1OC12
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 240
Group description: Scopolamine patch will be placed on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery.

scopolamine patch: Group I (n=80): Will receive scopolamine patch placement on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery. The time of the application of the patch will be recorded, and the time of the start of the surgery will be recorded. The last time point for evaluation of patient's nausea/vomiting will be when the patient arrives to the post anesthesia care unit. A member of the research team will remove the patch from the patient and properly dispose the patch upon arrival to the post anesthesia care unit.
Eligibility criteria:
Inclusion Criteria:

Female subjects ages 18 to 45
Subjects with ASA Class I or II
Subjects with elective primary or repeat cesarean delivery
Subjects who receive spinal and/or epidural anesthesia
English and non-English speaking subjects will be included in the study

Exclusion Criteria:

Female subjects <18 years of age
Subjects requiring emergent cesarean delivery
Gestational age < 37 weeks
History of placenta accreta
Multiple gestation pregnancy
ASA status III or higher
Current history of pregnancy induced hypertension, pre-eclampsia, or eclampsia
History of any chronic medication use (other than prenatal vitamins), including inhaler medications
Current urinary tract infection, pneumonia, or otitis media
Coagulopathies or skin infections overlying the spine
History of open angle glaucoma, seizures or psychosis
Intervention: Zeven
Trial phase: Phase 4
ATC code: J01XA04
SMILES: CNC1C(=O)NC2Cc3ccc(cc3)Oc3cc4cc(c3OC3OC(C(=O)O)C(O)C(O)C3NC(=O)CCCCCCCCC(C)C)Oc3ccc(cc3Cl)C(O)C3NC(=O)C(NC(=O)C4NC(=O)C(NC2=O)c2cc(cc(O)c2Cl)Oc2cc1ccc2O)c1ccc(O)c(c1)-c1c(OC2OC(CO)C(O)C(O)C2O)cc(O)cc1C(C(=O)NCCCN(C)C)NC3=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 153
Group description: The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.
Eligibility criteria:
Inclusion Criteria:

Presents to the Emergency Department (ED) and meets the clinical definition for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Known or suspected gram-positive infection.

Exclusion Criteria:

Known or suspected gram-negative infections, anaerobic infections, or fungemia
Known or suspected infections that are severe, life threatening or are not included in the ABSSSI Food and Drug Administration (FDA) guidance
Injection drug users with a fever
Severe neurological disorder leading to immobility or confined to a wheelchair
Bilateral Lower extremity involvement of the suspected infection.
Intervention: Nitroglycerin
Trial phase: Phase 4
ATC code: C01DA02 | C01DA52 | C05AE01
SMILES: O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 198
Group description: Sublingual Nitroglycerin spray of 0.8 mg

Patients will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan.
Eligibility criteria:
Inclusion Criteria:

Scheduled cCTA with contrast.
Able to comprehend and sign the consent form.

Exclusion Criteria:

Known hypersensitivity to glyceryl trinitrate, and related organic nitrates.
Acute circulatory failure associated with marked hypotension (shock).
Conditions associated with elevated intracranial pressure, cerebral haemorrhage and head trauma.
Closed-angle glaucoma.
Phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (Viagra®), tadalafil (Cialis), or vardenafil (Levitra) within the last 24 hours
Unstable clinical conditions (i.e. hemodynamic instability, arrhythmias)
Critical aortic stenosis
Systolic blood pressure < 90 mmHg
Pregnant or lactating female; premenopausal women with a positive urine pregnancy test.
Age under 18
Unwilling or unable to inform consent.
Intervention: Nitroglycerin
Trial phase: Phase 4
ATC code: C01DA02 | C01DA52 | C05AE01
SMILES: O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 198
Group description: Sublingual Nitroglycerin tablet of 0.8 mg

Patients will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan.
Eligibility criteria:
Inclusion Criteria:

Scheduled cCTA with contrast.
Able to comprehend and sign the consent form.

Exclusion Criteria:

Known hypersensitivity to glyceryl trinitrate, and related organic nitrates.
Acute circulatory failure associated with marked hypotension (shock).
Conditions associated with elevated intracranial pressure, cerebral haemorrhage and head trauma.
Closed-angle glaucoma.
Phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (Viagra®), tadalafil (Cialis), or vardenafil (Levitra) within the last 24 hours
Unstable clinical conditions (i.e. hemodynamic instability, arrhythmias)
Critical aortic stenosis
Systolic blood pressure < 90 mmHg
Pregnant or lactating female; premenopausal women with a positive urine pregnancy test.
Age under 18
Unwilling or unable to inform consent.
Intervention: Nitroglycerin
Trial phase: Phase 4
ATC code: C01DA02 | C01DA52 | C05AE01
SMILES: O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 198
Group description: Nitroglycerin skin patch of 0.8 mg/h

Patients categorized to transdermal administration will receive Nitroglycerin after Calcium scoring scan and 1 hour before the cCTA examination. The patch will be placed on the chest or the upper arm.
Eligibility criteria:
Inclusion Criteria:

Scheduled cCTA with contrast.
Able to comprehend and sign the consent form.

Exclusion Criteria:

Known hypersensitivity to glyceryl trinitrate, and related organic nitrates.
Acute circulatory failure associated with marked hypotension (shock).
Conditions associated with elevated intracranial pressure, cerebral haemorrhage and head trauma.
Closed-angle glaucoma.
Phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (Viagra®), tadalafil (Cialis), or vardenafil (Levitra) within the last 24 hours
Unstable clinical conditions (i.e. hemodynamic instability, arrhythmias)
Critical aortic stenosis
Systolic blood pressure < 90 mmHg
Pregnant or lactating female; premenopausal women with a positive urine pregnancy test.
Age under 18
Unwilling or unable to inform consent.
Intervention: Calcifediol
Trial phase: Phase 2
ATC code: A11CC06 | H05BX05
SMILES: C=C1CCC(O)CC1=CC=C1CCCC2(C)C1CCC2C(C)CCCC(C)(C)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 51
Group description: Calcifediol 400mcg PO/NGT/OGT x 1, followed by 200mcg PO/NGT/OGT daily x 4

Calcifediol: Calcifediol 400mcg PO/NGT/OGT x 1, followed by 200mcg PO/NGT/OGT daily x 4
Eligibility criteria:
Inclusion Criteria:

Age ≥ 18
Admitted to the ICU within 48h prior to enrollment
Likely to remain in the ICU (alive) for ≥72h
Naso/orogastric tube or ability to swallow
High risk of severe AKI

Exclusion Criteria:

Serum total calcium > 9.0 mg/dl or phosphate > 6.0 mg/dL within previous 48h
Currently receiving oral calcium supplementation
Ingestion of vitamin D3 >1,000 IU/day or any 25-hydroxyvitamin D or 1,25-dihydroxyvitamin D during the previous 7 days
AKI stage 2 or 3 (based on KDIGO serum creatinine and/or urine output criteria)
History of transplantation or receiving chronic (>7days) of immunosuppressive medications (not including glucocorticoid steroids at a dose less than or equivalent to prednisone 20 mg/day)
Neutropenia in the previous 48h
Active primary parathyroid disease, active granulomatous disease, or symptomatic nephrolithiasis in the previous 3 months
Receiving cytochrome P450 inhibitors
Chronic Kidney Disease stage V or End Stage Renal Disease
Hemoglobin < 7 g/dL
GI malabsorption
Prisoner
Pregnancy or breast feeding